论文部分内容阅读
目的对比70例不能手术的晚期胰腺癌患者单纯放射治疗与同期放化疗的疗效。方法 70例晚期胰腺癌患者随机分为两组。其中单纯放疗34例,同期放化疗36例,单纯放疗组放疗剂量为60Gy,同期放化疗组放疗剂量为50Gy,化疗方案为健择600mg/m2,每周一次,共4～6次。计算两组中位生存时间和1年生存率,并对比两组疗效。结果单纯放疗组中位生存期为7.4个月,1年生存率为14.4%,同期放化组中位生存期为9.5个月,1年生存率30.8%。两组治疗结束,其中腹痛缓解45例,无4级白细胞及血小板减少,未出现胰腺局部坏死,胃肠道穿孔及出血等严重并发症。结论同期放化疗治疗胰腺癌疗效明显好于单纯放疗,但毒副反应略重。
Objective To compare the efficacy of radiotherapy alone and concurrent chemoradiotherapy in 70 patients with unresectable advanced pancreatic cancer. Methods Seventy patients with advanced pancreatic cancer were randomly divided into two groups. Among them, 34 were radiotherapy alone and 36 were radiotherapy and chemotherapy in the same period. The radiotherapy dose was 60 Gy in the radiotherapy alone group and 50 Gy in the radiotherapy and chemotherapy group. The chemotherapy regimen was 600 mg / m2 gemcitabine once a week for 4 to 6 times. The median survival time and 1-year survival rate were calculated and compared between the two groups. Results The median survival time of radiotherapy alone group was 7.4 months. The 1-year survival rate was 14.4%. The median survival time was 9.5 months and the 1-year survival rate was 30.8%. Two groups of treatment ended, including 45 cases of abdominal pain relief, no grade 4 leukopenia and thrombocytopenia, no pancreatic necrosis, gastrointestinal perforation and bleeding and other serious complications. Conclusions The efficacy of concurrent chemoradiotherapy in the treatment of pancreatic cancer is better than that of radiotherapy alone, but the side effects are slight.